This segment focuses on the research and development of immunotherapies for infectious diseases, leveraging HOOKIPA's proprietary arenavirus platform. Research and development activities include preclinical studies, clinical trials, and collaborations with partners like Gilead Sciences. The company is developing product candidates like HB-101, currently in Phase II clinical trials for patients awaiting kidney transplantation from cytomegalovirus-positive donors. The technology utilizes arenaviruses to stimulate the immune system to fight against viral infections. The patient impact is significant, aiming to provide functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. Market positioning is based on a novel approach to immunotherapy, offering a potential advantage over traditional treatments. Future opportunities include expanding the pipeline to address other infectious diseases. Regulatory and clinical aspects involve navigating clinical trial phases and seeking regulatory approvals. Partnerships with Gilead Sciences are crucial for advancing the development and commercialization of these therapies.

This segment concentrates on developing immunotherapies for cancer treatment, specifically targeting human papillomavirus 16-positive cancers. HOOKIPA's arenavirus platform is used to create product candidates like HB-201 and HB-202, which are in Phase I/II clinical trials. Research and development efforts involve preclinical studies, clinical trial management, and the exploration of combination therapies. The technology utilizes the arenavirus platform to stimulate the immune system to recognize and eliminate cancer cells. The therapeutic focus is on cancers with high unmet medical needs. Patient impact aims to improve outcomes and survival rates for cancer patients. Market positioning is based on a novel approach to cancer immunotherapy, potentially offering advantages over existing treatments. Future opportunities include expanding the pipeline to address other cancer types and exploring combination therapies. Regulatory and clinical aspects involve navigating clinical trial phases and seeking regulatory approvals. The company is actively seeking partnerships to accelerate the development and commercialization of these oncology therapies.